Rose LifeScience has received a Cannabis Research Licence from Health Canada under the Cannabis Act. This authorization enables ROSE to focus on cannabis product innovations and developments.
For sanctioned cannabis producers, a Research Licence authorizing non-therapeutic research on cannabis permits in-house sensory and other consumer preference testing on many forms and derivatives of cannabis, with the intention of developing and refining products and technologies.
"This license increases our capacity to drive innovation, from fine-tuning strain profiles to identifying and validating value-added technologies," said Davide Zaffino, President and CEO, of ROSE. "With the freedom to test products internally, our ability to serve the customer and consumer improves. This means consumers across Canada can receive products that are more advanced and more understood in a much shorter timeline. This benefits everyone in our industry."
For more information:
ROSE LifeScience
2295 Chemin Ridge, Huntingdon, Québec, Canada, J0S 1H0
(450) 264-5434
roselifescience.ca